Multiple Myeloma

The FDA approval of daratumumab and hyaluronidase-fihj for high-risk smoldering MM shifts care beyond watchful waiting, notes Peter Voorhees, MD.

Although they covered diverse topics across the cancer continuum, the event’s 4 panel discussions shared a common focus on advancing more equitable and coordinated care.

Smarter therapies, evolving frailty tools, and more inclusive trials are finally extending myeloma's survival gains to older adults.

MajesTEC-9 supports moving teclistamab earlier in myeloma treatment, with robust PFS and OS gains over standard care in the second-line setting, notes Roberto Mina, MD.

Ajai Chari, MD, discusses how the results of the MajesTEC-3 trial may translate to a real-world second-line population with multiple myeloma.

Roberto Mina, MD, details how in the MajesTEC-9 trial, teclistamab monotherapy boosted PFS and OS in relapsed/refractory multiple myeloma, challenging standardized care.

Teclistamab had received an accelerated approval in October 2022; the combination regimen is administered subcutaneously.

Peter Voorhees, MD, explains how new daratumumab data shift smoldering multiple myeloma from watchful waiting to treatment.

Treatment for multiple myeloma often confers a higher risk of subsequent cardiovascular disease, but the impact of medications for the latter in this setting is not fully understood.

Ameet Patel, MD, concludes by outlining strategies to overcome operational, financial, and payer challenges in delivering advanced multiple myeloma therapies.

Ameet Patel, MD, explains how multiple myeloma treatment settings depend on safety, logistics, and patient needs.

Nicholas Richardson, DO, at Precision for Medicine, breaks down minimal residual disease and MRD negativity as FDA end points for faster myeloma approvals.

Ameet Patel, MD, discusses scaling CAR T-cell therapy and bispecific therapies to improve access and potentially cure multiple myeloma.

Targeted therapies, bispecifics, and CAR T-cell therapies are giving patients with multiple myeloma hope for long-term remission or a potential cure.

This approval brings the total indications for daratumumab and hyaluronidase to 5 in newly diagnosed disease and its 12th overall.

The results of the phase 3 MajesTEC-9 trial showcase teclistamab's efficacy for patients with relapsed/refractory multiple myeloma, explained Roberto Mina, MD.

Experts discuss the impact of biomarker testing on GU and lung cancers, as well as myeloma, emphasizing its role in personalized treatment and patient care advancements.

The FDA believes that data on MRD and complete response can expedite new drug delivery compared with long-term survival indicators.

Teclistamab was approved to treat relapsed/refractory multiple myeloma under the FDA’s accelerated approval pathway in October 2022.

Abstracts presented at ASH 2025 explore CAR T-cell therapy's effectiveness in newly authorized treatment centers, revealing promising outcomes for multiple myeloma patients and the prospect of expanded access.

Peter Voorhees, MD, emphasizes the importance of carefully determined early regimens for smoldering myeloma and involving patients in treatment decisions.

These are the most popular multiple myeloma articles from 2025.

Highlights from EHA 2025 included use of bispecific antibodies in more settings and novel approaches for improving outcomes in hard-to-treat patients.

Advances in radiopharmaceuticals, precision medicine, and the importance of diversity in clinical trials for multiple myeloma and cancer care were among the most popular articles with readers in 2025.